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Background: Purpose of the study was to investigate alterations in midbrain serotonin transporter (SERT) binding
in patients with epilepsy and symptoms of depression compared to patients with epilepsy with no symptoms of
depression.
Methods: We studied 12 patients with epilepsy (7 patients had focal and 5 had generalized epilepsy syndromes).
The presence of self-reported symptoms of depression was assessed using Beck Depression Inventory (BDI) and the
Emotional State Questionnaire (EST-Q). The binding potential of the SERT was assessed by performing brain single
photon emission tomography (SPET) using the SERT radioligand 2-((2-((dimethylamino)methyl)phenyl)thio)-5-(123)
iodophenylamine (123I-ADAM).
Results: Seven patients had BDI and EST-Q subscale scores greater than 11 points, which was interpreted as the
presence of symptoms of depression. We found that 123I-ADAM binding was not significantly different between
patients with epilepsy with and without symptoms of depression. In addition, 123I-ADAM binding did not show a
significant correlation to either BDI or EST-Q depression subscale scores and did not differ between patients with
focal vs. generalized epilepsy.
Conclusion: The results of our study failed to demonstrate alterations of SERT binding properties in patients with
epilepsy with or without symptoms of depression.
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The frequent coexistence of epilepsy and depression has
encouraged researchers to explore potential shared mech-
anisms underlying these disorders. Depression occurs
far more frequently in patients with epilepsy than in the
general population, affecting approximately 30% of this
patient population [1,2]. At the same time, the presence
of a psychiatric disorder, such as depression, has been
shown to reduce seizure threshold, and depression and
attempted suicide themselves are risk factors for epilepsy
[3-5]. These findings have led to the concept of a bidirec-
tional relation between epilepsy and depression [6]. This
issue is important, as the presence of depression is likely* Correspondence: maarika.liik@kliinikum.ee
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stated.to be the most important factor influencing quality of life
in patients with epilepsy [7,8], and can negatively impact
both medical and surgical treatment outcomes [9-11].
The dysfunction of the brain serotonin (5-hydroxy-
tryptamine or 5-HT) system has been suspected to be
the common denominator for the shared pathogenic
mechanisms of epilepsy and depression. Alterations in
serotonergic signaling are associated with the pathogen-
esis of depression in patients with major depressive
disorder - findings that are clinically supported by the
effect of selective serotonin reuptake inhibitors (SSRIs)
in the treatment of depression. Several neuroimaging
studies using different positron emission tomography
(PET) or single photon emission tomography (SPET)
tracers for various components of serotonergic system
in the brain have supported the involvement of 5-HT in
major depressive disorder. These alterations include. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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thalamus and limbic regions [12], or decreased brainstem
and midbrain SERT binding [13-15], as well as reduced 5-
HT1A receptor binding potential in various limbic and
neocortical regions and the raphe nuclei [16].
A growing body of evidence implicates the role of sero-
tonin system in epilepsy. This includes studies in which
the anticonvulsant effects of SSRIs have been confirmed,
such as Favale et al. [17]. In this study, citalopram was
administered to non-depressed patients with poorly con-
trolled epilepsy who then experienced a marked drop in
seizure frequency [17]. Previous neuroimaging works have
used PET tracers for 5-HT1A receptors to investigate the
role of the serotonergic system in epilepsy and depression.
These studies have concentrated on patients with both
temporal lobe epilepsy (TLE) and depression and have
shown reduced 5-HT1A receptor binding potential in the
ipsilateral temporal lobe as well as in thalamic regions,
hippocampus, anterior insula, anterior cingulate, and the
raphe nuclei in the depressed patients [18-20]. Thus, in
TLE patients with depression, there appear to be alter-
ations in the serotonergic system not only in the brain
regions affected by epilepsy, but also more generally in
ipsilateral and contralateral areas associated with regu-
lation of emotion, these are changes that are similar to
those described in patients with major depressive
disorder alone.
2-((2-((dimethylamino)methyl)phenyl)thio)-5-(123)iodo-
phenylamine (123I-ADAM) is a novel SPET tracer that has
shown a high binding affinity for SERT as well as high se-
lectivity for 5-HT transporter over those for norepineph-
rine and dopamine, and which has been proven to have
excellent brain uptake in rats [21]. Subsequently, other
studies demonstrated the feasibility of its use in human
subjects [22-25]. Newberg et al. [26] used SPET to demon-
strate alterations in SERT binding in patients with major
depression; in this study, SERT binding was decreased in
the midbrain region of patients with major depressive dis-
order and the degree of decrease correlated significantly
with the severity of depressive symptoms [26]. These find-
ings were generally corroborated by a later study by the
same group using a larger sample size [27]. However, to
our knowledge, no studies of SERT binding have been
conducted in patients with epilepsy.
The aim of the current study was to investigate SERT
binding in the midbrain of patients with epilepsy with
symptoms of depression, and to determine differences in




This study was approved by the Research Ethics Com-
mittee of the University of Tartu. We studied 12 patients(7 men and 5 women; ages ranging from 21 to 55 years;
mean age 36.3 ± 8.9 years) with epilepsy who were re-
cruited from the outpatient clinic at the Department of
Neurology and Neurosurgery in University of Tartu and
West-Tallinn Central Hospital in Tallinn, Estonia. Patients
were otherwise healthy, with no history of other neuro-
logical disorders except epilepsy, and did not use anti-
depressant medications prior to this study. All patients
gave informed consent to participate in the study.
In the current study, all patients with symptoms of
depression were consulted regarding their affective dis-
order, and treatment with antidepressant medications
was offered following the 123I-ADAM SPET study.
Assessment of symptoms of depression
Patients were screened for self-reported symptoms of
depression using the Beck Depression Inventory (BDI)
[28] and the Emotional State Questionnaire (EST-Q) [29].
Questionnaires were administered directly before the start
of the 123I-ADAM SPET imaging session. A cut-off score
of > 11 points was used to define the presence of symp-
toms of depression on the BDI. EST-Q is a self-report
questionnaire for depression and anxiety that uses the
rating of 33 items on a five-point frequency scale. This
questionnaire has five subscales: depression, anxiety,
agoraphobia–panic, fatigue, and insomnia. In the current
study, a cut-off score of > 11 points was used to define
the presence of symptoms of depression on the EST-Q
depression subscale.
Methods
We examined serotonin transporter (SERT) binding
potential by performing brain SPET study with 2-((2-
((dimethylamino)methyl)phenyl)thio)-5-(123)iodophenyla-
mine (123I-ADAM). The subjects received a dose of
185 MBq 123I-ADAM (MAP Medical Finland) intraven-
ously. To block the thyroid gland, potassium perchlo-
rate (KClO4; 800 mg) was given orally at least 20 min
prior to the injection of 123I-ADAM. Brain SPET studies
were acquired 4 hours after the injection of 123I-ADAM.
SPET studies were performed using a SPET/CT
INFINIA Hawkeye 4 (GE Healthcare) dual head
gamma camera with low energy high-resolution colli-
mators (Lehr collimators). The energy window was cen-
tered on 159 keV (+/−10%). SPET scans were acquired in
a step and shoot mode with total angular range of 360
degrees thereby arc per detector being 180 degrees.
View angle 3 degrees, 120 views, 30 sec per projection.
Acquisition time was 30 min. Matrix size was 128 ×
128, with a zoom of 1.0.
Data were reconstructed using the Xeleris Functional
Imaging Workstation software (GE Healthcare). Trans-
verse slices were reconstructed parallel to the cantho-
mental plane. SPET data were reconstructed using a
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followed by the Chang attenuation correction (threshold
5, coefficient 0.11). SPET and MRI data were automatically
coregistered using MPI Tool software (ATV Inc., Kerpen,
Germany). To measure the individual SERT occupancy,
irregular regions of interest (ROIs) were manually drawn
over the midbrain and over the cerebellum as the refer-
ence area. The 123I-ADAM binding was assessed using
MRI-guided ROIs in the midbrain and cerebellum. ROIs
were placed on transaxial MRI slices over the midbrain
and cerebellum and then transferred onto corresponding
SPET slices. In addition, radio-uptake and the specific
uptake ratios (SURs) of midbrain were assessed. As a
measure of brain SERT availability, the ratio of specific-
to-nonspecific 123I-ADAM binding for the midbrain com-
pared to the cerebellum were calculated in mean counts/
pixel using the following equation: SUR = specific binding/
nonspecific binding = target- cerebellum/cerebellum.
Statistical analysis
Statistical analysis was performed with STATISTICA 8.0.
Student’s t-tests were used to compare variables between
the two groups of patients (with symptoms of depression
vs. without symptoms of depression). A correlation analysis
was used to assess the relationship between depression
scale scores, demographic, and clinical characteristics, and
SERT binding potential.
Results
A summary of patient characteristics, including their
demographic and clinical characteristics is included in
Table 1. Seven patients had focal epilepsy; six of these
had had long-term EEG monitoring performed in order
to define focus localization. Of these seven patients, six
patients had TLE (two with right sided and four with left
sided TLE) and one patient had probable frontal lobe
epilepsy (FLE; lateralization to the right side). Five pa-
tients had generalized epilepsy syndrome. MRI scans for
the generalized epilepsy patients were all normal. On the
MRI, three patients with focal epilepsy presented with
mesial temporal sclerosis, one with hippocampal atro-
phy, and one with cysts in temporomesial structures.
Epilepsy could be considered treatment resistant in the
majority of the patients, eight of whom were on polyther-
apy with antiepileptic drugs (AEDs). The patients with
focal epilepsy, as a group, were comparable to the patients
with generalized epilepsy regarding age, age at epilepsy on-
set, epilepsy duration, use of AEDs, as well as their mean
BDI and EST-Q questionnaire scores.
Seven patients had BDI and EST-Q depression subscale
scores greater than 11 points, which was interpreted as
the presence of symptoms of depression. The mean BDI
and EST-Q depression subscale scores for the whole
patient group were 11.5 ± 6 and 14 ± 4.3, respectively.The maximal BDI score was 20; in all patients with
symptoms of depression, the BDI score was in the
range of mild to moderate severity.
In the current study, patients with symptoms of depres-
sion, as a group, did not significantly differ from patients
without symptoms of depression in either demographic or
clinical variables (Table 2). A comparison of these patient
groups indicated that patients with symptoms of depres-
sion showed a trend towards a longer duration of epilepsy,
which did not reach statistical significance.
Using SPET, we observed that 123I-ADAM binding to
SERT did not differ significantly between the patients with
epilepsy who had symptoms of depression vs. those with-
out. In addition, SERT binding potential of 123I-ADAM
did not show any statistically significant correlation with
either the BDI or the EST-Q depression subscale scores.
SERT binding potential was also not correlated with any
demographic or clinical characteristics, including age, dur-
ation of epilepsy, or age at disease onset. We also observed
that the SERT binding potential did not differ between
patients with focal vs. generalized epilepsy.
One patient with moderate symptoms of depression on
BDI committed suicide shortly following the 123I-ADAM
imaging study.
Discussion
In the current study, we sought to study SERT binding
properties in the midbrain region in patients with epilepsy,
and to determine whether SERT binding differed between
depressed vs. non-depressed patients with epilepsy. Our
results did not indicate any difference in SERT binding
potential between these patient groups.
There could be several reasons for these negative results.
Previous work with PET and SPET tracers for SERT in de-
pressed patients has shown some conflicting results. The
majority of reports show increased SERT binding in the
thalamus and limbic regions of depressed patients com-
pared to controls [30], but others have shown decreased
SERT binding potential in the amygdala and midbrain of
depressed patients [13-15]. Studies using 123I-ADAM
SPET to measure SERT binding in major depressive
disorder have also indicated decreased SERT binding in
the midbrain, medial temporal lobe, and basal ganglia of
depressed patients compared to controls [26,27]. At the
same time, however, reports showing no differences in
midbrain SERT availability for 123I-ADAM in patients
with depression compared to healthy controls have also
been published [31,32]. It has been hypothesized that,
in case of major depressive disorder, the SERT binding
potential is elevated, but that in major depressive
disorder with comorbid psychiatric illnesses, regional
SERT binding could be decreased [12]. Taking this into
account, and considering the fact that there are no
SERT binding studies done in patients with epilepsy, it

















32 M 17 15 2-5/mo Generalized N/A Generalized
spike-wave
activity
Not performed Normal LEV (2000) No 1.3
VPA (1800)
LTG (75)
24 F 5 19 1/mo Generalized N/A Generalized
spike-wave
activity
Not performed Normal VPA (1500) No 1.39
OXC (1200)
36 M 21 15 1/year Generalized N/A Negative Not performed Normal VPA (600) No 0.87






Normal LTG (400) Yes 1.36
OXC (600)
55 M 23 32 1/mo Generalized N/A Generalized
spike-wave
activity
Not performed Normal VPA (2000) Yes 1.16
LTG (150)





Small cysts in left
temporomesial structures,
hippocampus and amygdala
LTG (250) No 1.42







Colloidal cyst in left
frontotemporal regions
PB (50) No 1.1
LTG (200)
38 M 22 16 1/mo Focal Left temporal Negative Not performed Hippocampal atrophy on
the left side
OXC (1800) Yes 0.98
VPA (900)








on the right side
PHT (375) Yes 1.28
42 F 14 28 2/mo Focal Right frontal Negative Right frontal
ictal activity
2 small hyperintensive
lesions in the right parietal
lobe
OXC (1800) Yes 1.46








on the left side
VPA (1000) Yes 1.32
TPM (100)








on the right side
OXC (1800) Yes 1.26
TPM (400)
EEG – electroencephalography; LTM – long-term monitoring; MRI – magnetic resonance imaging; AEDs – antiepileptic drugs; LEV – levetiracetam; VPA – valproate; LTG – lamotrigin; OXC – oxcarbazepine;


















Table 2 Comparison of clinical characteristics, depression questionnaire results and midbrain SERT binding affinity on
123I-ADAM between groups of patients with symptoms of depression (BDI and EST-Q score > 11 points) and without
symptoms of depression
Symptoms of depression (n=7) No symptoms of depression (n=5) P-value
Age 37.7 (± 10.5) 34.2 (±6.5) NS
Age at onset 12.4 (±8.4) 18.8 (±8.6) NS
Duration of epilepsy 25.3 (±10.8) 15.4 (±2.5) NS
BDI 15.3 (±3.8) 6.0 (±1.4) 0.004
EST-Q 15.8 (±2.6) 7.0 (±1.0) 0.04
123I-ADAM binding to SERT 1.26 (±0.2) 1.216 (±0.2) NS
NS – not significant; BDI – Beck Depression Inventory; EST-Q - Emotional State Questionnaire; 123I-ADAM – 2-((2-((dimethylamino)methyl)phenyl)thio)-5-
(123)iodophenylamine; SERT – serotonin transporter.
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in SERT binding in patients with epilepsy and comorbid
depression. Addressing this hypothesis more fully would
likely require a study with a larger sample size.
Another contributing factor to these negative results
may be the genetic variability that has been shown for
SERT expression in the human brain. For example, indi-
viduals with polymorphisms in the promoter (5-HTTLPR)
of the SLC6A4 gene, which encodes the SERT protein,
exhibit differences in SERT binding properties in neuro-
imaging studies [33-35]. Genetic studies have shown that
there may even be an association between the presence of
the combined 5-HTTLPR and 5-HTTVNTR genotype,
which results in less efficient transcription of SERT, and
the presence of TLE [36]. Genetic variability of SERT
expression may influence the development of affective
disorders, it would likely affect SERT imaging studies, and
could even be related to epileptogenesis. Unfortunately, in
the current study, we did not genotype our patients for
polymorphisms in SLC6A4.
There are several limitations to the current study. Per-
haps the most important, and the one likely to be largely
responsible for our negative results, is the relatively small
study sample size. The statistical power of the comparison
of SERT binding in groups of patients with and without
depression was 0.755. We calculated that increasing the
power to 0.8 under the same conditions would need 40
subjects, which considering the nature and cost of SPET
imaging, would be unachievable.
Since in all patients with symptoms of depression, the
BDI score was in the range of mild to moderate severity,
it could also be considered as a weakness contributing
to the negative results of our study.
The heterogeneity of our study group, regarding the
clinical characteristics of epilepsy, could also have led to
the observed lack of differences in SERT binding proper-
ties. The characteristics of depression, depression-related
treatment outcomes, and serotonergic system involve-
ment, based on 5-HT1A receptor imaging studies, are all
well-documented in cases of TLE. Little is known aboutthe same aspects in case of focal extra-temporal epilepsies,
and even less about generalized epilepsy syndromes. Al-
though some findings have indicated that depression could
be specifically related to TLE and mesial temporal scler-
osis [37], this has not been confirmed by other reports
[38]. It has been shown that the prevalence of depression
is similar between patients with TLE and FLE. There are
no reports of focal vs. generalized epilepsy in terms of the
prevalence of depression. One work did assess symptoms
of anxiety, and found that patients with FLE have much
higher anxiety scores than patients with generalized epi-
lepsy [39]. In our study, groups of patients with focal vs.
generalized epilepsy were comparable in terms of presence
of depressive symptoms.
These previous findings seem to indicate that the bidir-
ectional relationship between epilepsy and depression is
not specific to TLE. It has been shown that preoperative
depressive symptoms predict postoperative seizure out-
come in both TLE and FLE [11]. Therefore, common
pathogenic mechanisms may be involved in the etiology of
depression comorbid with different epilepsy syndromes,
and we would expect that this should be demonstrable in
patients having different clinical characteristics of epilepsy,
such as those included in the current study. Our findings
support the notion that depression and the involvement
of the serotonergic system in various epilepsy syndromes
requires a deeper exploration with further studies.
Conclusions
The results of our study failed to demonstrate alterations
of SERT binding potential in patients with epilepsy with
symptoms of depression compared to patients with epi-
lepsy without symptoms of depression. Further studies are
needed to clarify the role of SERT and, more generally, the




(123)iodophenylamine; SPET: Single photon emission tomography;
SERT: Serotonin transporter; BDI: Beck depression inventory; EST-Q: Emotional
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